Distocur 34 mg/ml Oral suspension for cattle and sheep

Ireland - English - HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:
Available from:
Dopharma Research B.V.
ATC code:
INN (International Name):
34 milligram(s)/millilitre
Pharmaceutical form:
Oral suspension
Prescription type:
LM: Licensed Merchant as defined in relevant national legislation
Therapeutic area:
Authorization status:
Authorization number:
Authorization date:

Health Products Regulatory Authority

02 August 2019


Page 1 of 4

Summary of Product Characteristics


Distocur 34 mg/ml Oral suspension for cattle and sheep


Each ml contains:

Active substance:


34.0 mg


Methyl parahydroxybenzoate (E218)

1.35 mg

Propyl parahydroxybenzoate

0.15 mg

For the full list of excipients, see section 6.1.


Oral suspension.

Whitish to beige suspension.


4.1 Target Species

Cattle and sheep.

4.2 Indications for use, specifying the target species

Cattle and sheep:

Treatment of infections caused by the adult stage of Fasciola hepatica, sensitive to oxyclozanide.

Elimination of gravid tapeworm segments (Moniezia spp.).

4.3 Contraindications

Do not use in cases of known hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings for each target species

To date no resistance to oxyclozanide has been reported. Use of the product should be based on local (regional, farm)

epidemiological information about susceptibility of trematodes and recommendations on how to limit further selection for

resistance to anthelmintics.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could

ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

- Underdosing, which may be due to underestimation of body weight, misadministration of the product or lack of calibration of

the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg

Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic

belonging to another pharmaceutical class and having a different mode of action should be used.

At normal dose levels, oxyclozanide is not active against immature flukes present in liver tissue.

Milking cattle, particularly high yielders, may show a reduction in yield, occasionally of 5 % or more, for about 48 hours after

handling. The effect of this small loss may be minimised by spreading herd dosing over a period of about one week.

Health Products Regulatory Authority

02 August 2019


Page 2 of 4

4.5 Special precautions for use

Special precautions for use in animals

To avoid damage to the pharyngeal region, care should be taken when administering by dosing gun.

Adverse effects (see section 4.6) are occasionally enhanced in animals suffering from severe liver damage and/or dehydration

at the time of dosing.

Due regard must always be given to the physical condition of animals undergoing treatment, particularly those in advanced

pregnancy and/or under stress from adverse weather conditions, poor nutrition, penning, handling, etc.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

This veterinary medicinal product may cause irritation to skin, eyes and mucous membranes.

People with known hypersensitivity to oxyclozanide or any of the excipients should avoid contact with the veterinary medicinal


Wash hands after use.

Operators should wear rubber gloves when applying the product.

Do not smoke, eat or drink while handling the product.

In case of contact with the product, rinse the affected area immediately with plenty of water.

Contaminated clothing should be removed immediately.

In the event of accidental ingestion, seek medical advice.

Other precautions

Oxyclozanide is toxic to dung fauna and aquatic organisms. The risk can be reduced by avoiding too frequent and repeated

use of oxyclozanide in cattle. Treated cattle must not graze near watercourses and must not have access to water bodies for 5

days after treatment.

4.6 Adverse reactions (frequency and seriousness)

Slight softening of the faeces with animal showing increased frequency of defecation and transient inappetence may appear

very rarely.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated )

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Laboratory studies during different phases of reproduction have not produced any evidence of teratogenic or foetotoxic

effects, or negative effects on fertility.

Can be used during pregnancy and lactation.

However care should be taken when treating heavily pregnant animals and animals under stress from adverse weather

conditions, poor nutrition, penning, handling etc.

4.8 Interaction with other medicinal products and other forms of interactions

No information is available on the safety and efficacy of this veterinary medicinal product when used with any other veterinary

medicinal product.

A decision to use this veterinary medicinal product before or after any other veterinary medicinal product therefore needs to

be made on a case by case basis.

4.9 Amounts to be administered and administration route

Oral use. Give as an oral drench. Shake the suspension at least 5 times before use.

To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the

dosing device should be checked. If animals are to be treated collectively rather than individually, they should be grouped

according to their bodyweight and dosed accordingly, in order to avoid under – or overdosing.

Health Products Regulatory Authority

02 August 2019


Page 3 of 4


Dose according to body weight at a rate of 10 mg oxyclozanide per kg body weight, corresponding to 3 ml of product per 10

kg body weight. For animal above 350 kg, dose is 3.5 g oxyclozanide per animal, i.e. 103 ml of product.


Dose according to body weight at a rate of 15 mg oxyclozanide per kg body weight, corresponding to 4.4 ml of product per 10

kg body weight. For animal above 45 kg, dose is 0.68 g oxyclozanide per animal, i.e. 20 ml of product.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

The adverse reactions (see section 4.6) observed at normal doses are more pronounced at increased doses. At doses of 50

mg/kg there is a risk of death.

The effects of oxyclozanide overdosage are dullness and some loosening of faeces in sheep and possible diarrhoea,

inappetance and loss of weight in cattle. These effects are very rarely enhanced in animals with severe liver damage and/or

dehydration at the time of dosing.

4.11 Withdrawal period(s)


Meat and offal: 13 days.

Milk: 4.5 days (108 hours).


Meat and offal: 14 days.

Milk: 7 days (168 hours).


Pharmacotherapeutic group: Anthelmintics, Phenol derivatives, incl. salicylanilides, oxyclozanide

ATCvet code: QP52AG06

5.1 Pharmacodynamic properties

Oxyclozanide is an anthelmintic of the salicylanilide group. The salicylanilides are proton ionophores, which act as specific

uncouplers of mitochondrial oxidative phosphorylation, disrupting the metabolism of the parasite.

The chemical structure of salicylanilides is characterised by the presence of an unstable proton. They are lipophilic molecules

which allow the passage of protons across membranes, especially through the inner mitochondrial membrane.

Oxyclozanide has flukicidal activity against the adult stage of Fasciola hepatica. Its efficacy against cestodes is limited to the

removal of segments of the tapeworm Moniezia.

5.2 Pharmacokinetic particulars

Oxyclozanide is slowly absorbed after oral administration.

In cattle, the peak plasma concentration (nearly 13 micrograms/ml) is observed 13 hours after administration. The mean

elimination half-life is 11 hours.

In sheep, the peak plasma concentration (nearly 31 micrograms/ml) is observed 18 hours after administration. The mean

elimination half-life is 11 hours.

Excretion is predominantly faecal with biliary excretion being the most important route of elimination.

Environmental properties

Faeces containing oxyclozanide excreted onto pasture by treated animals may reduce the abundance of dung feeding

organisms which may impact on dung degradation.

Oxyclozanide is toxic to aquatic organisms. Oxyclozanide is persistent in soils.

Health Products Regulatory Authority

02 August 2019


Page 4 of 4


6.1 List of excipients

Methyl parahydroxybenzoate (E218)

Propyl parahydroxybenzoate

Aluminium magnesium silicate

Carmellose sodium (E466)

Sodium laurilsulfate

Monohydrate citric acid (E330)

Sodium citrate (E331)

Purified water

6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal


6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the container: use within 1 year.

6.4 Special precautions for storage

Do not store above 25°C after first opening.

6.5 Nature and composition of immediate packaging

One white high density polyethylene container (1L, 5L and 10L) closed by one white high density polyethylene cap.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the

use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be

disposed of in accordance with local requirements.


Dopharma Research B.V.

Zalmweg 24

4941 VX Raamsdonksveer





Date of first authorisation: 13 January 2017


August 2019

Similar products

Search alerts related to this product

View documents history

Share this information